Teva one of 2 finalists in Merck KGaA tender - report

Indias The Economic Times: Other contender is a consortium of Indian Pharmaceuticals and US equity funds.

Indias The Economic Times reports that Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) may be one of the two finalists in the tender for the generic business of Germanys Merk KGaA (XETRA:MRK). The other finalist is a consortium of Indias Torrent Pharmaceuticals Ltd. (BSE: 500420) and US equity funds Fortress Investment Group and Greater Pacific Capital, after Mylan Laboratories Inc. (NYSE:MYL) and Icelands Actavis Group HF (IC:ACT) dropped out of the race

The Economic Times cites unconfirmed reports suggest that the acquisition of Mercks generics business could be in excess of $5 billion.

Published by Globes [online], Israel business news - - on March 25, 2007

Copyright of Globes Publisher Itonut (1983) Ltd. 2007

Twitter Facebook Linkedin RSS Newsletters Israel Business Conference 2018